Skip to main content
TipRanks
Go Ultimate75% OFF

Mach7 Technologies (TDMMF) AI Stock Analysis

14 Followers
TDMMF

Mach7 Technologies

(Other OTC:TDMMF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring Revenue BaseThe predominantly recurring revenue mix provides greater visibility than one-time license sales and supports repeatable customer economics. ARR growth of 7.6% on a constant-currency basis indicates underlying subscription and support expansion that could compound if customer retention and module adoption improve.
Negative Factors
Revenue and Profitability WeaknessThe sharp revenue decline and substantial net loss show that Mach7 has not yet converted its software model and high gross margin into sustainable profitability. Continued losses could constrain investment capacity and make execution of the FY27 growth plan more dependent on a successful commercial recovery.

Mach7 Technologies (TDMMF) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%40%TDMMF-58.20%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$49.19M
Dividend Yield
―
Average Volume (3M)
6,812
Price to Earnings (P/E)
-7.1
Beta (1Y)
0.41
Revenue Growth
-13.39%
EPS Growth
-53.61%
Country
US
Employees
167
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Mach7 Technologies Business Overview & Revenue Model

Company Description

Mach7 Technologies Limited develops and commercializes medical imaging and data management software solutions for healthcare organizations in North America, the Asia Pacific, the Middle East, Europe, and internationally. It offers eUnity enterprise d...

Mach7 Technologies Earnings Call Summary

Earnings Call Date:Aug 27, 2026(Q4-2026)|% Change Since:4.50%|Next Earnings Date:Mar 03, 2027
Earnings Call SentimentPositive

The call presented a cautious but constructive tone: FY'26 was framed as a deliberate reset that materially improved the business foundation—higher-quality recurring revenue mix, a 93% gross margin, reduced operating costs, a stronger leadership team, and clear second-half commercial momentum (ARR run rate +7.6% constant currency; H2 revenue +15% vs H1). However, meaningful near-term challenges remain including a 17% reported revenue decline, several sizable customer losses (notably VHA and Trinity Health), an $8.9M net loss, and FX-driven reporting headwinds. Management emphasized stabilization and a roadmap (Flamingo modules, Epic integrations, focused partnerships) to prove growth in FY'27. Overall, positives around margin, cash/no debt, cost discipline and H2 recovery modestly outweigh the lowlights, supporting cautious optimism.

Positive Updates

Predominantly Recurring Revenue Base
Total revenue of $27.9M for FY'26 with $23.4M of recurring revenue; contracted ARR (CAR) $25.5M and ARR run rate $23.5M, reflecting a more subscription-driven, predictable revenue mix.

Negative Updates

Year-on-Year Revenue Decline
Total revenue declined 17% versus prior year (as reported), driven primarily by lower capital license revenue and softer professional services.

Company Guidance

Management set four clear FY‑27 priorities—ARR growth, new customer wins, Flamingo adoption and OpEx discipline—and gave FY‑26 baselines to measure progress: FY‑26 total revenue $27.9M (recurring $23.4M), CAR $25.5M and an ARR run‑rate of $23.5M; revenue was down 17% YoY (recurring down 8%), capital license revenue $1.5M (‑17%), while ARR run‑rate was up 7.6% on a constant‑currency basis and CAR was down 9% constant currency. They closed FY‑26 with operating expenses $26.7M (down $5.1M or 16%), gross margin 93%, adjusted EBITDA loss of $0.9M, net loss before amortization $2.9M, net loss after tax $8.9M, cash $19.9M and no debt; cash receipts were $28M and operating cash flow was negative for the year but positive in 3 of 4 quarters (Q1 ‑$3.7M, Q2 ~breakeven, Q3 +$1.2M, Q4 +$1.1M). Second‑half momentum (constant‑currency revenue H2 $15.6M vs H1 $13.5M, +15%), stronger bookings (TCV up 80% H2 vs H1; 86% ARR‑type; 40% of orders in Q4; 21% new logos) and one‑offs (restructuring $1.9M, deferred tax write‑off ≈$1M) provide the starting point for proving recurring revenue growth, module adoption and operating leverage in FY‑27.

Mach7 Technologies Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TDMMF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:PMEAU:PME76OutperformAUD 21.07B79.3963.19%0.34%22.87%130.30%
AU:ALCAU:ALC69NeutralAUD 168.73M70.592.53%―26.61%38.21%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:ONEAU:ONE48NeutralAUD 100.70M-5.74-203.69%―-1.53%28.29%
AU:AYAAU:AYA46NeutralAUD 476.83M-16.67-30.04%―<0.01%2.08%
AU:BMTAU:BMT45NeutralAUD 19.79M-1.06-58.13%―2.08%-195.31%

* Healthcare Sector Average

Performance Comparison

-50%0%50%TDMMFAU:ONEAU:PMEAU:BMTAU:AYAAU:ALCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TDMMF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TDMMFMach7 Technologies Ltd.0.21-0.29-58.20%
AU:ONEOneview Healthcare PLC Chess Depository Interests repr 10.12-0.17-58.62%
AU:PMEPro Medicus Limited201.65-50.16-19.92%
AU:BMTBeamtree Holdings Ltd0.07-0.13-66.50%
AU:AYAArtrya Limited2.90-0.27-8.52%
AU:ALCAlcidion Group Limited1.250.2525.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.